View Exam | PowerPak

1. Which of the following nonopioid analgesics has a dose-dependent mechanism of action?

A. Amitriptyline B. Aspirin C. Acetaminophen D. Celecoxib E. Unsure

2. Per the American College of Physicians, a first-line pharmacologic option for patients with chronic low back pain with an inadequate response to nonpharmacologic interventions is:

A. NSAIDs B. Duloxetine C. Cyclobenzaprine D. Pregabalin E. Unsure

3. All of the following patient populations may be at an increased risk for NSAID-induced nephrotoxicity EXCEPT:

A. Patients concurrently administered hydrochlorothiazide B. Patients with heart disease C. Patients > 60 years of age D. Patients who drink ≥ 3 alcoholic drinks per day E. Unsure

4. Per the American Headache Society, an adjuvant nonopioid agent with established efficacy in migraine prevention is:

A. NSAIDs B. Amitriptyline C. Venlafaxine D. Topiramate E. Unsure

5. Hepatotoxicity is a potentially serious adverse effect of acetaminophen. What is the maximum recommended total daily dose of acetaminophen in order to avoid hepatic damage in the majority of patients?

A. 2 grams B. 4 grams C. 3 grams D. 5 grams E. Unsure

6. Per the American Diabetes Association, pregabalin is a recommended initial treatment option for symptomatic patients with diabetic neuropathy. What is a usual oral pregabalin dosage for this indication?

A. 100 mg IR capsule 3 times daily B. 300 mg ER tablet once daily C. 330 mg IR capsule twice daily D. 300 mg IR capsule 3 times daily E. Unsure

7. The FDA has warned about serious breathing difficulties with the use of:

A. Topiramate B. Duloxetine C. Gabapentin D. Oxcarbazepine E. Unsure

8. Which of the following drug-drug interactions could potentially result in a decrease in renal function?

A. NSAIDs/warfarin B. Cyclobenzaprine/alprazolam C. NSAIDs/ACE inhibitors D. Aspirin/warfarin E. Unsure

9. The CDC guideline for prescribing opioids for chronic pain recommends:

A. Nonopioid treatments as preferred options for chronic pain management in all patients B. Nonopioid treatments as preferred options for chronic pain management in patients not in active cancer treatment, palliative care, or end-of-life care C. Nonpharmacologic treatments initially with nonopioid treatments administered only after a failure to respond D. Nonopioid treatments in combination with opioids for chronic pain management of all patients E. Unsure

10. Which of the following is an appropriate oral maintenance dose of celecoxib for treatment of acute pain?

A. 200 mg once daily B. 100 mg twice daily C. 200 mg twice daily D. 100 mg once daily E. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following nonopioid analgesics has a dose-dependent mechanism of action?

2. Per the American College of Physicians, a first-line pharmacologic option for patients with chronic low back pain with an inadequate response to nonpharmacologic interventions is:

3. All of the following patient populations may be at an increased risk for NSAID-induced nephrotoxicity EXCEPT:

4. Per the American Headache Society, an adjuvant nonopioid agent with established efficacy in migraine prevention is:

5. Hepatotoxicity is a potentially serious adverse effect of acetaminophen. What is the maximum recommended total daily dose of acetaminophen in order to avoid hepatic damage in the majority of patients?

6. Per the American Diabetes Association, pregabalin is a recommended initial treatment option for symptomatic patients with diabetic neuropathy. What is a usual oral pregabalin dosage for this indication?

7. The FDA has warned about serious breathing difficulties with the use of:

8. Which of the following drug-drug interactions could potentially result in a decrease in renal function?

9. The CDC guideline for prescribing opioids for chronic pain recommends:

10. Which of the following is an appropriate oral maintenance dose of celecoxib for treatment of acute pain?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following nonopioid analgesics has a dose-dependent mechanism of action?

2. Per the American College of Physicians, a first-line pharmacologic option for patients with chronic low back pain with an inadequate response to nonpharmacologic interventions is:

3. All of the following patient populations may be at an increased risk for NSAID-induced nephrotoxicity EXCEPT:

4. Per the American Headache Society, an adjuvant nonopioid agent with established efficacy in migraine prevention is:

5. Hepatotoxicity is a potentially serious adverse effect of acetaminophen. What is the maximum recommended total daily dose of acetaminophen in order to avoid hepatic damage in the majority of patients?

6. Per the American Diabetes Association, pregabalin is a recommended initial treatment option for symptomatic patients with diabetic neuropathy. What is a usual oral pregabalin dosage for this indication?

7. The FDA has warned about serious breathing difficulties with the use of:

8. Which of the following drug-drug interactions could potentially result in a decrease in renal function?

9. The CDC guideline for prescribing opioids for chronic pain recommends:

10. Which of the following is an appropriate oral maintenance dose of celecoxib for treatment of acute pain?

« Return to Activity

Customers who Purchased
this Activity also Purchased